Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening

Enzalutamide, docetaxel, and cabazitaxel treatment resistance is a major problem in metastatic castration resistant prostate cancer (mCRPC), but the underlying genetic determinants are poorly understood. To identify genes that modulate treatment response to these drugs, we performed three genome-wid...

Descripción completa

Detalles Bibliográficos
Autores principales: Haldrup, Jakob, Weiss, Simone, Schmidt, Linnéa, Sørensen, Karina Dalsgaard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239467/
https://www.ncbi.nlm.nih.gov/pubmed/37270558
http://dx.doi.org/10.1038/s41598-023-35950-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239467/
https://www.ncbi.nlm.nih.gov/pubmed/37270558
http://dx.doi.org/10.1038/s41598-023-35950-7

Ejemplares similares